Compositions and Methods for Assessing and Treating Inflammatory Diseases and Disorders

• US 20140377278A1
• Filed: 04/16/2012
• Published: 12/25/2014
• Est. Priority Date: 01/10/2012
• Status: Abandoned Application

• Current Assignee: Yale University
• Original Assignee: Yale University
• Inventors: Flavell, Richard A., Strowig, Till, Elinav, Eran, Mejia, Jorge H., Jin, Chengcheng
• Application Number:
  US14/343,098
• Publication Number:
  US 20140377278A1
• Time in Patent Office: Days
• US Class Current: 424/158.1
• CPC Class Codes: A61K 2035/115 Probiotics
• CPC Class Codes: A61K 35/741 Probiotics probiotic yeast, e.g. saccharomyces A61K36/06
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: C12Q 1/6869 Methods for sequencing
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material

Abstract

The present invention relates to the discovery that the disruption of inflammasome function leads to an altered microbiota that affects the development and progression of inflammatory diseases and disorders. Thus, the invention relates to compositions and methods for detecting and determining the relative proportions of the constituents of a subject'"'"'s microbiota, methods of modifying an altered microbiota population in a subject, and compositions and methods for treating inflammatory diseases and disorders in a subject in need thereof.

Claims

1. A method of diagnosing an altered microbiota associated with an inflammatory disease or disorder in a subject in need thereof, the method comprising the steps of:

a. obtaining a fecal sample from a subject,

b. obtaining bacterial nucleic acid from the fecal sample,

c. amplifying the bacterial nucleic acid using PCR,

d. sequencing the amplicons resulting from the amplification of the bacterial nucleic acid using PCR,

e. identifying the types of bacteria present in the biological sample obtained from the subject by detecting nucleic acid sequences that are specific to particular types of bacteria,

f. quantifying the types of bacteria present in the biological sample obtained from the subject by quantifying nucleic acid sequences that are specific to particular types of bacteria,

g. determining the relative proportions of the types of bacteria present in the fecal sample obtained from the subject,

h. comparing the relative proportions of the types of bacteria present in the fecal sample obtained from the subject with the relative proportions of the types of bacteria present in a normal microbiota,

i. wherein when at least one Lactobacillus spp. is under-represented in the biological sample obtained from the subject, as compared with a normal microbiota, and

ii. wherein when at least one type of bacteria selected from the group consisting of Prevotellaceae, TM7, Porphyromonadaceae, and Erysipelotrichaceae is over-represented in the biological sample obtained from the subject, as compared with a normal microbiota,

i. the subject is diagnosed with an altered microbiota associated with an inflammatory disease or disorder.

2. The method of claim 1, wherein the bacterial nucleic acid is 16S rRNA.

3. The method of claim 1, wherein the inflammatory disease or disorder is at least one inflammatory disease or disorder selected from the group consisting of:

inflammatory bowel disease, celiac disease, colitis, intestinal hyperplasia, metabolic syndrome, obesity, rheumatoid arthritis, liver disease, hepatic steatosis, fatty liver disease, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

4. (canceled)

5. A method of treating an inflammatory disease or disorder associated with an altered microbiota in a subject in need thereof, by modifying the altered microbiota to that of a normal microbiota, the method comprising the steps of:

a. administering to the subject at least one type of bacteria that is under-represented in the altered microbiota of the subject, and

b. administering to the subject at least one antibiotic to diminish the numbers of at least one type of bacteria that is overrepresented in the altered microbiota.

6. The method of claim 5, wherein the at least one type of bacteria that is under-represented in the altered microbiota is at least one Lactobacillus spp.

7. The method of claim 5, wherein at least one Lactobacillus spp. is administered to the subject.

8. The method of claim 5, wherein the at least one type of bacteria that is overrepresented in the altered microbiota is at least one of Prevotellaceae, TM7, Porphyromonadaceae, and Erysipelotrichaceae.

10. The method of claim 5, wherein the inflammatory disease or disorder is at least one inflammatory disease or disorder selected from the group consisting of:

inflammatory bowel disease, celiac disease, colitis, intestinal hyperplasia, metabolic syndrome, obesity, rheumatoid arthritis, liver disease, hepatic steatosis, fatty liver disease, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

9. (canceled)

11. (canceled)

12. A method of treating an inflammatory disease or disorder associated with an altered microbiota in a subject in need thereof, the method comprising:

administering to the subject a therapeutically effective amount of a composition comprising a CCL5 inhibitor.

13. The method of claim 12, wherein the CCL5 inhibitor is an antibody that specifically binds to CCL5.

15. The method of claim 12, wherein the CCL5 inhibitor is an antisense nucleic acid.

17. The method of claim 12, wherein the CCL5 inhibitor is at least one selected from the group consisting of:

a chemical compound, a protein, a peptide, a peptidomemetic, a ribozyme, and a small molecule chemical compound.

18. The method of claim 12, wherein the inflammatory disease or disorder is at least one inflammatory disease or disorder selected from the group consisting of:

inflammatory bowel disease, celiac disease, colitis, intestinal hyperplasia, metabolic syndrome, obesity, rheumatoid arthritis, liver disease, hepatic steatosis, fatty liver disease, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

14. (canceled)

16. (canceled)

19. (canceled)

20. A method of treating an inflammatory disease or disorder associated with an altered microbiota in a subject in need thereof, the method comprising:

administering to the subject a therapeutically effective amount of a composition comprising a CCL5 receptor inhibitor.

21. The method of claim 20, wherein the CCL5 receptor is at least one selected from the group consisting of:

CCR1, CCR3, CCR4, CCR5 and GPR75.

22. The method of claim 20, wherein the CCL5 receptor inhibitor is an antibody that specifically binds to a CCL5 receptor.

24. The method of claim 20, wherein the CCL5 receptor inhibitor is an antisense nucleic acid.

26. The method of claim 20, wherein the CCL5 receptor inhibitor is at least one selected from the group consisting of:

a chemical compound, a protein, a peptide, a peptidomemetic, a ribozyme, and a small molecule chemical compound.

27. The method of claim 20, wherein the inflammatory disease or disorder is at least one inflammatory disease or disorder selected from the group consisting of:

inflammatory bowel disease, celiac disease, colitis, intestinal hyperplasia, metabolic syndrome, obesity, rheumatoid arthritis, liver disease, hepatic steatosis, fatty liver disease, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

23. (canceled)

25. (canceled)

28. (canceled)